NCT05281237Recruiting
Avecure Flexible Microwave Ablation Probe For Lung Nodules
Feasibility and Efficacy of the AveCure Flexible Microwave Ablation Probe for Peripheral Lung Nodule
Source: ClinicalTrials.gov · Last updated 8 Apr 2026
Brief summary (registry, in English)
This research study to determine the effectiveness of the AveCure Flexible Microwave Ablation Probe to destroy cancerous lung nodules up to 3 c m in size. This research study involves microwave ablation (MWA)
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 10 (estimated)
- First submitted
- 16 Feb 2022
- Start date
- 1 Jun 2022
- Primary completion date
- 30 Dec 2026
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Diseases
- Lung cancer
- NCT number
- NCT05281237
What you commit to
- Study type: Interventional
- Planned participants: 10
- From 1 Jun 2022 to the primary completion date, 30 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior radiation or neo adjuvant chemotherapy of the target nodule/tumor
Other illness
- Patients in other therapeutic lung cancer studies
- COVID-19 positive patient at the time of procedure.
Other
- Subjects in whom flexible bronchoscopy is contraindicated
- Target nodule \< 1.0 cm
- Any comorbidity that the investigator feels would interfere with the safety of the subject or the evaluation of study objectives
- Pacemaker, implantable cardioverter, or another electronic implantable device
- Patient cannot tolerate bronchoscopy
- Patients with coagulopathy
- Subject is pregnant or breastfeeding
Who the study is looking for
- Subject with Stage I - II primary lung cancer (Solitary nodules up to 3 cm) as defined by previous pathology or ROSE.
- Pathological proof of target nodule/tumor type and malignancy with specimen considered adequate per institutional laboratory standards
- Target nodule/tumor which can be accessed via navigational bronchoscopy and confirmed location with cone beam CT scan intra-operatively
- Resection/surgical candidate (lobectomy or greater)
- Participants must be at least 22 years old and able to provide consent
Age in the registry: 22 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Beth Israel Deaconess Medical Center Coordinator of this site? Confirm its status | Boston | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.